Pharmacokinetics and Pharmacodynamics — MCQs

A 32-year-old female presents to the Gynecology OPD with complaints of prolonged vaginal bleeding, lasting longer than her usual menstrual period. Physical examination reveals no significant findings. Further history indicates the patient has been on warfarin therapy for one year and recently started a new medication before the onset of symptoms. Which of the following medications is least likely to interact with warfarin and cause or exacerbate bleeding?

Q287Easy

What is the most important channel of elimination of digoxin?

Q288Easy

Which of the following factors does NOT determine the dosage of a drug?

Q289Medium

A drug is administered with a loading dose of 20 mg, resulting in a plasma concentration of 0.5 mg/L. If the apparent volume of distribution is 40 L, calculate the bioavailability of the drug.

Q290Medium

Which of the following drugs' absorption is increased in gastric achlorhydria?

Pharmacokinetics and Pharmacodynamics Indian Medical PG Practice Questions and MCQs

Question 281: Acidic drugs bind to which of the following plasma proteins?

A. Globulin
B. Alpha-1 glycoprotein
C. Albumin (Correct Answer)
D. None of the above

Explanation: **Explanation:** The binding of drugs to plasma proteins is a crucial pharmacokinetic parameter that determines a drug's distribution and elimination. **1. Why Albumin is Correct:** **Albumin** is the most abundant plasma protein and possesses multiple binding sites with a high affinity for **acidic drugs**. This is primarily due to the electrostatic attraction between the negatively charged acidic drug molecules and the basic amino acid residues (like lysine and arginine) present on the albumin molecule. * **Examples of drugs binding to Albumin:** Warfarin, Phenytoin, Salicylates (Aspirin), Penicillins, and Sulfonamides. **2. Why Other Options are Incorrect:** * **Alpha-1 Acid Glycoprotein (AAG):** This protein primarily binds to **basic drugs** (e.g., Propranolol, Lidocaine, Quinidine). It is an acute-phase reactant, meaning its levels increase during inflammation, surgery, or cancer, which can alter the free fraction of basic drugs. * **Globulins:** While certain globulins act as specific carriers for endogenous substances (e.g., Transcortin for cortisol, Sex hormone-binding globulin), they are not the primary binding site for most acidic pharmacological agents. **3. High-Yield Clinical Pearls for NEET-PG:** * **The "Free" Fraction:** Only the unbound (free) drug is pharmacologically active, can cross membranes, and is available for metabolism and excretion. * **Displacement Interactions:** If two drugs compete for the same binding site on albumin (e.g., Sulfonamides and Bilirubin in neonates), one can displace the other. This can lead to toxicity, such as **Kernicterus** in newborns. * **Hypoalbuminemia:** In conditions like Nephrotic Syndrome or Liver Cirrhosis, decreased albumin levels lead to an increase in the free fraction of acidic drugs, potentially causing toxicity even at standard doses.

Question 282: Maintenance dose is primarily dependent on which pharmacokinetic parameter?

A. Clearance (Correct Answer)
B. Volume of distribution
C. Metabolism
D. Absorption

Explanation: **Explanation:** The primary goal of a **maintenance dose** is to maintain a steady-state plasma concentration ($C_{ss}$) of a drug, where the rate of drug administration equals the rate of drug elimination. **1. Why Clearance (A) is correct:** The mathematical formula for maintenance dose is: $$\text{Maintenance Dose} = \frac{C_{ss} \times \text{Clearance}}{\text{Bioavailability (F)}}$$ Since the dose is intended to replace only the amount of drug lost from the body, it is directly proportional to **Clearance (CL)**. If a patient has impaired clearance (e.g., renal failure), the maintenance dose must be decreased to avoid toxicity. **2. Why other options are incorrect:** * **Volume of Distribution (Vd):** This parameter determines the **Loading Dose**, not the maintenance dose. Vd relates the total amount of drug in the body to the plasma concentration but does not account for the rate of elimination over time. * **Metabolism:** While metabolism is a component of clearance, it is not the only one (excretion also plays a role). Clearance is the more comprehensive pharmacokinetic parameter used for dosing calculations. * **Absorption:** This affects the bioavailability (F) and the peak concentration, but the maintenance dose is calculated based on the target steady-state level regardless of how the drug enters the systemic circulation (though F is used as a correction factor). **Clinical Pearls for NEET-PG:** * **Loading Dose** = $(Vd \times \text{Target } C_{ss}) / F$. Think: *Vd for Loading, Clearance for Maintenance.* * **Steady State:** It takes approximately **4 to 5 half-lives** to reach steady-state concentration. * **Half-life ($t_{1/2}$):** Is determined by both Vd and CL ($t_{1/2} = 0.693 \times Vd / CL$).

Question 283: Which of the following is NOT a phase I drug metabolism reaction?

A. Oxidation
B. Deamination
C. Dealkylation
D. Sulfation (Correct Answer)

Explanation: Drug metabolism (biotransformation) typically occurs in two phases to make lipophilic drugs more water-soluble for excretion. **Why Sulfation is the correct answer:** **Sulfation** is a **Phase II (Conjugation) reaction**. Phase II reactions involve the attachment of an endogenous hydrophilic group (like glucuronic acid, sulfate, or glutathione) to a drug or its Phase I metabolite. This significantly increases water solubility and usually results in pharmacological inactivation. Other Phase II reactions include Glucuronidation (most common), Acetylation, and Methylation. **Why the other options are incorrect:** Phase I reactions (Functionalization) introduce or expose a functional group (–OH, –NH2, –SH) on the drug molecule. * **Oxidation (Option A):** The most common Phase I reaction, primarily mediated by Cytochrome P450 enzymes. * **Deamination (Option B):** The removal of an amino group from a molecule, a classic Phase I process (e.g., metabolism of adrenaline by MAO). * **Dealkylation (Option C):** The removal of alkyl groups (like methyl or ethyl) from a drug, also a Phase I oxidative process. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Phase II:** **"S-G-A-M"** (Sulfation, Glucuronidation, Acetylation, Methylation). * **Microsomal vs. Non-microsomal:** Most Phase I and Glucuronidation occur in the Smooth ER (microsomal). Sulfation and Acetylation are **non-microsomal** (cytosolic). * **Exception to Inactivation:** Phase II usually inactivates drugs, but **Morphine-6-glucuronide** is a Phase II metabolite that is *more* active than morphine. * **Grey Baby Syndrome:** Occurs due to deficient Glucuronidation of Chloramphenicol in neonates.

Question 284: All of the following factors tend to increase the volume of distribution of a drug except?

A. High plasma protein binding (Correct Answer)
B. Low ionization at physiological pH values
C. High lipid solubility
D. High tissue binding

Explanation: **Explanation:** The **Volume of Distribution ($V_d$)** is a theoretical volume that relates the total amount of drug in the body to its concentration in the plasma ($V_d = \text{Amount of drug} / \text{Plasma concentration}$). A high $V_d$ indicates that the drug has left the vascular compartment and distributed into tissues. **Why Option A is correct:** **High plasma protein binding** (e.g., to albumin) keeps the drug molecules "trapped" within the vascular compartment. Since the drug cannot easily cross capillary membranes while bound to proteins, the plasma concentration remains high, resulting in a **low $V_d$**. Therefore, high plasma protein binding decreases, rather than increases, the $V_d$. **Why the other options are incorrect:** * **B. Low ionization:** Non-ionized drugs are lipid-soluble and can easily cross biological membranes to enter tissues, thereby **increasing $V_d$**. * **C. High lipid solubility:** Lipid-soluble drugs (e.g., Thiopentone) easily cross the blood-brain barrier and cell membranes, distributing extensively into adipose and other tissues, which **increases $V_d$**. * **D. High tissue binding:** Drugs with a high affinity for specific tissue proteins (e.g., Digoxin binding to cardiac muscle) are sequestered outside the plasma, leading to a very **high $V_d$** (often exceeding the total body water). **NEET-PG High-Yield Pearls:** * **Chloroquine** has one of the highest $V_d$ values (~13,000 L) due to extensive tissue binding. * Drugs with **low $V_d$** (e.g., Heparin, Warfarin) are largely confined to the vascular compartment and are easily removed by hemodialysis. * **Loading Dose** calculation is directly dependent on $V_d$ ($\text{LD} = V_d \times \text{Target Plasma Concentration}$).

Question 285: An acidic drug is more ionized at which pH?

A. Alkaline pH (Correct Answer)
B. Acidic pH
C. Neutral pH
D. None of the above

Explanation: **Explanation:** The ionization of a drug depends on its chemical nature (pKa) and the pH of the surrounding medium [1]. This concept is governed by the **Henderson-Hasselbalch equation**. **1. Why Alkaline pH is Correct:** An acidic drug (HA) acts as a proton donor. In an **alkaline (basic) environment**, there is a low concentration of hydrogen ions ($H^+$). To reach equilibrium, the acidic drug dissociates to release $H^+$, becoming negatively charged ($A^-$). Therefore, **acidic drugs are more ionized in alkaline media** and more unionized in acidic media [1]. **2. Why Other Options are Incorrect:** * **Acidic pH:** In an acidic medium, there is an abundance of $H^+$ ions. This suppresses the dissociation of an acidic drug (Le Chatelier's principle), keeping it in its **unionized (lipid-soluble)** form. * **Neutral pH:** While some ionization occurs at pH 7.0, it is not the *maximal* point of ionization for an acidic drug compared to a truly alkaline environment. **Clinical Pearls & High-Yield Facts for NEET-PG:** * **Lipid Solubility:** Only the **unionized** form of a drug is lipid-soluble and can cross biological membranes (e.g., GI absorption, Blood-Brain Barrier). * **Ion Trapping:** This principle is used in the **management of drug poisoning** [2]. To accelerate the excretion of an acidic drug (like **Aspirin or Barbiturates**), we **alkalinize the urine** using Sodium Bicarbonate [2]. This "traps" the drug in its ionized form in the renal tubules, preventing reabsorption. * **Mnemonic:** *"Like dissolves in Like"* (Acidic drugs are unionized/absorbed in acidic media; Basic drugs are unionized/absorbed in basic media).

Question 286: A 32-year-old female presents to the Gynecology OPD with complaints of prolonged vaginal bleeding, lasting longer than her usual menstrual period. Physical examination reveals no significant findings. Further history indicates the patient has been on warfarin therapy for one year and recently started a new medication before the onset of symptoms. Which of the following medications is least likely to interact with warfarin and cause or exacerbate bleeding?

A. Clarithromycin
B. Sulfonamide
C. Ciprofloxacin
D. Carbamazepine (Correct Answer)

Explanation: **Explanation:** The clinical presentation describes a patient on **Warfarin** experiencing increased bleeding (prolonged vaginal bleeding), suggesting an elevation in the International Normalized Ratio (INR). This occurs when a drug inhibits the metabolism of warfarin or when a drug induces its metabolism is stopped. **1. Why Carbamazepine is the correct answer:** Carbamazepine is a potent **Cytochrome P450 (CYP) enzyme inducer** (specifically CYP2C9, 1A2, and 3A4). By inducing these enzymes, it increases the rate of warfarin metabolism, leading to **decreased plasma levels** of warfarin and a **reduced anticoagulant effect**. Therefore, Carbamazepine would decrease the risk of bleeding (potentially causing clots instead), making it the *least likely* to cause or exacerbate bleeding in this patient. **2. Why the other options are incorrect:** * **Clarithromycin (A):** A Macrolide antibiotic that is a potent **CYP3A4 inhibitor**. It decreases warfarin metabolism, increasing its concentration and the risk of bleeding. * **Sulfonamides (B):** These inhibit **CYP2C9** (the primary enzyme for S-warfarin) and can also displace warfarin from plasma protein binding sites, significantly increasing the INR. * **Ciprofloxacin (C):** A Fluoroquinolone that inhibits **CYP1A2 and CYP3A4**, leading to reduced warfarin clearance and increased bleeding risk. **Clinical Pearls for NEET-PG:** * **S-Warfarin** is 3-5 times more potent than R-warfarin and is primarily metabolized by **CYP2C9**. * **Mnemonic for Enzyme Inducers (GPRS Cell Phone):** **G**riseofulvin, **P**henytoin, **R**ifampicin, **S**moking, **C**arbamazepine, **P**henobarbitone. * **Mnemonic for Enzyme Inhibitors (VITAMIN K):** **V**alproate, **I**soniazid, **T**ame (Cimetidine), **A**miodarone, **M**acrolides (except Azithromycin), **I**t ranozole (Ketoconazole), **N**eomycin, **K**uinolones (Ciprofloxacin).

Question 287: What is the most important channel of elimination of digoxin?

A. Glomerular filtration (Correct Answer)
B. Tubular secretion
C. Hepatic metabolism
D. Excretion in bile

Explanation: **Explanation:** **1. Why Glomerular Filtration is Correct:** Digoxin is a cardiac glycoside primarily eliminated by the kidneys. Approximately **60-80%** of the drug is excreted **unchanged** in the urine. The primary mechanism for this renal clearance is **glomerular filtration**. Because its elimination is directly proportional to the Glomerular Filtration Rate (GFR), the dose of digoxin must be strictly adjusted based on creatinine clearance to avoid toxicity. **2. Why the Other Options are Incorrect:** * **Tubular secretion (B):** While digoxin does undergo some active tubular secretion (mediated by P-glycoprotein), it is not the *most important* channel compared to the volume handled by filtration. * **Hepatic metabolism (C):** Only a small fraction (about 15-20%) of digoxin is metabolized by the liver. This is in contrast to **Digitoxin**, which is primarily metabolized by the liver (making Digitoxin safer in renal failure but rarely used now). * **Excretion in bile (D):** Biliary excretion and enterohepatic circulation play a negligible role in the overall elimination of digoxin. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Half-life ($t_{1/2}$):** Digoxin has a long half-life of approximately **36-40 hours** in patients with normal renal function. * **Renal Failure:** In anuric patients, the half-life can extend to **>5 days**. * **P-glycoprotein (P-gp) Interactions:** Drugs like **Quinidine, Verapamil, and Amiodarone** inhibit P-gp, reducing the tubular secretion of digoxin and significantly increasing its plasma levels, leading to toxicity. * **Monitoring:** Due to its narrow therapeutic index (0.5–2 ng/mL) and renal dependence, monitoring serum electrolytes (especially Potassium) is crucial, as **hypokalemia** predisposes to digoxin toxicity.

Question 288: Which of the following factors does NOT determine the dosage of a drug?

A. Volume of distribution
B. Half-life
C. Lipid solubility
D. None of the above (Correct Answer)

Explanation: **Explanation:** In pharmacokinetics, the dosage of a drug is determined by its ability to reach and maintain therapeutic concentrations in the body. All three factors listed (Volume of distribution, Half-life, and Lipid solubility) are critical determinants of dosing regimens. Therefore, "None of the above" is the correct answer as all options influence dosage. 1. **Volume of Distribution ($V_d$):** This determines the **Loading Dose**. Drugs with a high $V_d$ sequester into tissues and require a larger initial dose to achieve the desired plasma concentration ($Loading\ Dose = V_d \times Target\ Plasma\ Concentration$). 2. **Half-life ($t_{1/2}$):** This determines the **Dosing Interval** (frequency of administration). Drugs with short half-lives require more frequent dosing or continuous infusions to maintain a steady state, whereas drugs with long half-lives can be dosed less frequently. 3. **Lipid Solubility:** This dictates the drug's ability to cross biological membranes. Highly lipid-soluble drugs usually have a larger $V_d$ and longer half-lives (due to storage in adipose tissue), directly impacting both the amount and frequency of the dose. **High-Yield Clinical Pearls for NEET-PG:** * **Clearance ($CL$):** The most important factor in determining the **Maintenance Dose**. * **Steady State:** Reached after approximately **4 to 5 half-lives**, regardless of the dose or frequency. * **Loading Dose Calculation:** Does not depend on clearance; it depends solely on $V_d$ and target concentration. * **Bioavailability ($F$):** Must be considered for oral dosing ($Dose = \frac{Target\ Concentration \times CL}{F}$).

Question 289: A drug is administered with a loading dose of 20 mg, resulting in a plasma concentration of 0.5 mg/L. If the apparent volume of distribution is 40 L, calculate the bioavailability of the drug.

A. 70%
B. 80%
C. 90%
D. 100% (Correct Answer)

Explanation: ### Explanation **1. Understanding the Correct Answer (D: 100%)** The relationship between Loading Dose (LD), Volume of Distribution (Vd), Target Plasma Concentration (Cp), and Bioavailability (F) is defined by the formula: **$\text{Loading Dose (LD)} = \frac{Vd \times Cp}{F}$** Rearranging the formula to find Bioavailability (F): **$F = \frac{Vd \times Cp}{LD}$** Plugging in the values from the question: * $Vd = 40\text{ L}$ * $Cp = 0.5\text{ mg/L}$ * $LD = 20\text{ mg}$ $F = \frac{40 \times 0.5}{20} = \frac{20}{20} = 1$ A bioavailability of **1** is equivalent to **100%**. This indicates that the drug reached the systemic circulation completely unchanged, which is characteristic of intravenous (IV) administration. **2. Why Other Options are Incorrect** * **Options A, B, and C (70%, 80%, 90%):** These values would result in a lower plasma concentration than 0.5 mg/L for the same dose. For instance, if the bioavailability were 80% (0.8), the resulting concentration would be: $Cp = \frac{LD \times F}{Vd} = \frac{20 \times 0.8}{40} = 0.4\text{ mg/L}$. Since the actual concentration achieved matches the theoretical maximum for that dose and volume, the bioavailability must be 100%. **3. Clinical Pearls & High-Yield Facts for NEET-PG** * **Bioavailability (F):** Defined as the fraction of an administered dose of unchanged drug that reaches the systemic circulation. For IV drugs, $F = 100\%$ by definition. * **Loading Dose:** Used to achieve the steady-state concentration ($C_{ss}$) rapidly. It depends primarily on the **Volume of Distribution**. * **Maintenance Dose:** Used to maintain the $C_{ss}$ by replacing the drug lost through elimination. It depends primarily on **Clearance (CL)**. * **Vd Concept:** If Vd is high (>42L), the drug is sequestered in tissues (lipophilic); if Vd is low, the drug remains in the plasma (highly protein-bound or large molecules).

Question 290: Which of the following drugs' absorption is increased in gastric achlorhydria?

A. Ketoconazole
B. Penicillin G (Correct Answer)
C. Chloramphenicol
D. Ciprofloxacin

Explanation: ### Explanation The absorption of drugs is significantly influenced by gastric pH. **Gastric achlorhydria** (absence of hydrochloric acid) results in a higher (more alkaline) gastric pH, which affects the stability and ionization of certain drugs. **Why Penicillin G is the correct answer:** Penicillin G is **acid-labile**, meaning it is rapidly degraded by gastric acid. In a normal stomach, a significant portion of the drug is destroyed before it can reach the site of absorption. In patients with achlorhydria, the lack of acid prevents this degradation, leading to higher stability of the drug in the stomach and, consequently, **increased systemic absorption.** **Analysis of Incorrect Options:** * **Ketoconazole:** This is a weak base that requires an acidic environment for dissolution and ionization. In achlorhydria, its solubility decreases, leading to **decreased absorption.** (Same applies to Itraconazole). * **Ciprofloxacin:** Fluoroquinolones generally require an acidic environment for optimal dissolution. Their absorption is typically **reduced** or delayed when gastric pH increases (e.g., with antacids or PPIs). * **Chloramphenicol:** Its absorption is not significantly affected by gastric pH changes as it is well-absorbed regardless of the acid status of the stomach. **NEET-PG High-Yield Pearls:** * **Acid-Labile Drugs:** Penicillin G, Erythromycin, and Digoxin. Their bioavailability increases if gastric acidity is low. * **Drugs requiring Acid for Absorption:** Ketoconazole, Itraconazole, Iron salts, and Vitamin B12. Their absorption decreases in achlorhydria or with long-term PPI use. * **Clinical Correlation:** Patients on Proton Pump Inhibitors (PPIs) may show altered pharmacokinetics similar to those with achlorhydria. Always check for drug-drug interactions involving pH changes.

Practice by Chapter

Absorption and Bioavailability

Practice Questions

Drug Distribution and Protein Binding

Practice Questions

Biotransformation and Metabolism Pathways

Practice Questions

Renal and Non-renal Excretion

Practice Questions

Compartment Models

Practice Questions

Dose-Response Relationships

Practice Questions

Drug Efficacy and Potency

Practice Questions

Drug Tolerance and Tachyphylaxis

Practice Questions

Population Pharmacokinetics

Practice Questions

Pharmacokinetic Variability

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free